FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2785719984> ?p ?o ?g. }

• W2785719984 abstract "Epidermal growth factor receptor (EGFR) mutations enable constitutive active downstream signaling of PI3K/AKT, KRAS/ERK and JAK/STAT pathways, and promote tumor progression by inducing uncontrolled proliferation, evasion of apoptosis and migration of non-small cell lung cancer (NSCLC). In addition, such EGFR mutations increase the susceptibility of patients with NSCLC to tyrosine kinase inhibitor (TKI) therapy, but treated patients will invariably relapse with resistant disease. A global understanding of underlying molecular mechanisms of EGFR signaling may improve the management of NSCLC patients. microarray analysis was performed to identify PI3K/AKT-regulated miRNAs. Phosphoproteomic analysis and cell based assays were performed using NSCLC cell lines lentivirally transduced with anti-miR or miR overexpressing constructs. Here, we show that 17 miRNAs including members of the miR-17~ 92 cluster are dysregulated following PI3K/AKT inhibition of EGFR mutant NSCLC cells. Bioinformatics analysis revealed that dysregulated miRNAs act in a concerted manner to enhance the activity of the EGFR signaling pathway. These findings were closely mirrored by attenuation of miR-17~ 92 family member miR-19b in NSCLC cell lines which resulted in reduced phosphorylation of ERK, AKT and STAT and effector proteins in EGFR mutant NSCLC cells. Consistent with this finding, cell cycle progression, clonogenic growth and migration were reduced and apoptosis was enhanced. Co-treatment of NSCLC cells with the tyrosine kinase inhibitor (TKI) gefitinib and anti-miR-19b construct reduced migration and clonogenic growth in a synergistic manner suggesting that EGFR and miR-19b act together to control oncogenic processes. Serine/threonine phosphatase PP2A subunit PPP2R5E and BCL2L11 encoding BIM were identified as major targets of miR-19b by target validation assays. Consistent with this finding, PP2A activity was strongly enhanced in NSCLC transduced with anti-miR-19b construct, but not in cells co-transduced with anti-miR-19b and shPPP2R5E, suggesting that PPP2R5E is a major constituent of the PP2A complex. Accordingly, enhanced proliferation by miR-19b was due to targeting PPP2R5E. In contrast, apoptosis resistance was mainly due to targeting BCL2L11. Our results provide insight into the importance of targeting PPP2R5E and BCL2L11 by miR-19b in oncogenic processes of NSCLC. Attenuation of miR-19b expression could potentially be exploited in adjuvant therapy of EGFR mutant NSCLC." @default.
• W2785719984 created "2018-02-23" @default.
• W2785719984 creator A5022774077 @default.
• W2785719984 creator A5025157687 @default.
• W2785719984 creator A5032572194 @default.
• W2785719984 creator A5032995318 @default.
• W2785719984 creator A5043145814 @default.
• W2785719984 creator A5082283904 @default.
• W2785719984 date "2018-02-19" @default.
• W2785719984 modified "2023-10-17" @default.
• W2785719984 title "miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer" @default.
• W2785719984 cites W1561854825 @default.
• W2785719984 cites W1819171550 @default.
• W2785719984 cites W1963952027 @default.
• W2785719984 cites W1969003435 @default.
• W2785719984 cites W1970015742 @default.
• W2785719984 cites W1971626394 @default.
• W2785719984 cites W1984386151 @default.
• W2785719984 cites W2000333606 @default.
• W2785719984 cites W2016927106 @default.
• W2785719984 cites W2030166934 @default.
• W2785719984 cites W2032541751 @default.
• W2785719984 cites W2039827956 @default.
• W2785719984 cites W2048225142 @default.
• W2785719984 cites W2052705131 @default.
• W2785719984 cites W2057480888 @default.
• W2785719984 cites W2062290101 @default.
• W2785719984 cites W2074201366 @default.
• W2785719984 cites W2081783238 @default.
• W2785719984 cites W2083115283 @default.
• W2785719984 cites W2085592081 @default.
• W2785719984 cites W2094478005 @default.
• W2785719984 cites W2100324029 @default.
• W2785719984 cites W2100592123 @default.
• W2785719984 cites W2111742556 @default.
• W2785719984 cites W2114664968 @default.
• W2785719984 cites W2116365126 @default.
• W2785719984 cites W2124808167 @default.
• W2785719984 cites W2125545284 @default.
• W2785719984 cites W2135657761 @default.
• W2785719984 cites W2149296979 @default.
• W2785719984 cites W2156057678 @default.
• W2785719984 cites W2166084034 @default.
• W2785719984 cites W2168289490 @default.
• W2785719984 cites W2168928584 @default.
• W2785719984 cites W2180481128 @default.
• W2785719984 cites W2206185841 @default.
• W2785719984 cites W2404927328 @default.
• W2785719984 cites W2405571000 @default.
• W2785719984 cites W2489370798 @default.
• W2785719984 cites W2539939673 @default.
• W2785719984 cites W2555005730 @default.
• W2785719984 cites W2580426837 @default.
• W2785719984 cites W2599001146 @default.
• W2785719984 cites W2603695819 @default.
• W2785719984 cites W2612939089 @default.
• W2785719984 cites W2613638456 @default.
• W2785719984 cites W2617352970 @default.
• W2785719984 cites W2806575069 @default.
• W2785719984 doi "https://doi.org/10.1186/s12943-018-0781-5" @default.
• W2785719984 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5817797" @default.
• W2785719984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29455644" @default.
• W2785719984 hasPublicationYear "2018" @default.
• W2785719984 type Work @default.
• W2785719984 sameAs 2785719984 @default.
• W2785719984 citedByCount "68" @default.
• W2785719984 countsByYear W27857199842018 @default.
• W2785719984 countsByYear W27857199842019 @default.
• W2785719984 countsByYear W27857199842020 @default.
• W2785719984 countsByYear W27857199842021 @default.
• W2785719984 countsByYear W27857199842022 @default.
• W2785719984 countsByYear W27857199842023 @default.
• W2785719984 crossrefType "journal-article" @default.
• W2785719984 hasAuthorship W2785719984A5022774077 @default.
• W2785719984 hasAuthorship W2785719984A5025157687 @default.
• W2785719984 hasAuthorship W2785719984A5032572194 @default.
• W2785719984 hasAuthorship W2785719984A5032995318 @default.
• W2785719984 hasAuthorship W2785719984A5043145814 @default.
• W2785719984 hasAuthorship W2785719984A5082283904 @default.
• W2785719984 hasBestOaLocation W27857199841 @default.
• W2785719984 hasConcept C117262875 @default.
• W2785719984 hasConcept C121608353 @default.
• W2785719984 hasConcept C190283241 @default.
• W2785719984 hasConcept C2777609662 @default.
• W2785719984 hasConcept C2779438470 @default.
• W2785719984 hasConcept C2780580887 @default.
• W2785719984 hasConcept C502942594 @default.
• W2785719984 hasConcept C54355233 @default.
• W2785719984 hasConcept C55493867 @default.
• W2785719984 hasConcept C57074206 @default.
• W2785719984 hasConcept C62112901 @default.
• W2785719984 hasConcept C62478195 @default.
• W2785719984 hasConcept C75217442 @default.
• W2785719984 hasConcept C86554907 @default.
• W2785719984 hasConcept C86803240 @default.
• W2785719984 hasConcept C95444343 @default.
• W2785719984 hasConceptScore W2785719984C117262875 @default.
• W2785719984 hasConceptScore W2785719984C121608353 @default.
• W2785719984 hasConceptScore W2785719984C190283241 @default.
• W2785719984 hasConceptScore W2785719984C2777609662 @default.

• next